Post-Marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - A Preliminary Study to Evaluate the co-Primary Endpoint in Patients (Male) With Diarrhea-Predominant Irritable Bowel Syndrome.

Trial Profile

Post-Marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - A Preliminary Study to Evaluate the co-Primary Endpoint in Patients (Male) With Diarrhea-Predominant Irritable Bowel Syndrome.

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Oct 2015

At a glance

  • Drugs Ramosetron (Primary)
  • Indications Irritable bowel syndrome
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 23 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Jan 2010 Actual patient number (98) added as reported by ClinicalTrials.gov.
    • 25 Jun 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top